-The Telegraph The proliferation and sales of anti-diabetes combination pills that contain two drugs to control blood sugar has stirred concerns in medical circles that a large proportion of diabetes patients in India are not receiving ideal treatment. A study by Indian and British researchers has shown that such two-drug combo pills accounted for more than half of the sales of all oral anti-diabetes medications in India last year, although doctors say...

-The Economic Times MUMBAI: The Union Cabinet this week passed an ordinance to implement the National Food Security Bill (NFSB). The bill guarantees legal entitlement of food grains at a subsidised price to ~67 per cent of India's population. The ordinance will come into effect immediately once it is signed by the President. But it also needs to be approved by both the houses of Parliament in the monsoon session within six...

-PTI India however maintained that the India Patent Act was in accordance with the TRIPS Agreement & the Paris Convention The US Pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied. "PhRMA remains concerned about the deteriorating intellectual property environment in India," Mark Grayson, PhRMA spokesman told PTI. The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's...

-The Hindu That India, the pharmacy of the South, should find itself on the brink of a major TB-drug stock-out is at once shocking and shameful. The fact that an antiquated drug-procurement system and incompetent and irresponsible government departments - which dragged their feet for more than two long years to procure the drugs - could have brought us to such a situation tells us how dangerously poised the national...

-The Times of India NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been "of unacceptable quality". Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable...